olanzapine + reboxetine

Olanzapine + reboxetine is a combination of two pharmaceutical agents used primarily in research and off-label clinical practice. Olanzapine is an atypical antipsychotic that acts as an antagonist at dopamine D2, serotonin 5-HT2A, histamine H1, muscarinic acetylcholine, and adrenergic receptors. It is widely used for the treatment of schizophrenia and bipolar disorder. Reboxetine is a selective norepinephrine reuptake inhibitor (NRI) antidepressant that increases synaptic norepinephrine levels by inhibiting its transporter. The combination has been studied for its potential to attenuate olanzapine-induced weight gain and metabolic disturbances in patients with schizophrenia or related disorders. Clinical studies have shown that adding reboxetine to olanzapine therapy can reduce weight gain, decrease appetite, improve certain metabolic parameters (such as triglycerides and leptin), and may be well tolerated[1][2][5]. This combination does not have a unique brand name or fixed-dose formulation approved by regulatory agencies; it is typically prescribed as co-administration of the individual drugs.